MCID: PNC033
MIFTS: 44

Pancreas Adenocarcinoma malady

Categories: Endocrine diseases, Cancer diseases

Aliases & Classifications for Pancreas Adenocarcinoma

About this section

Aliases & Descriptions for Pancreas Adenocarcinoma:

Name: Pancreas Adenocarcinoma 32 10 12
Adenocarcinoma of the Pancreas 10
 
Adenocarcinoma of Pancreas 65
Pancreatic Adenocarcinoma 10

Classifications:



External Ids:

Disease Ontology10 DOID:4074
SNOMED-CT59 700423003
NCIt42 C8294
UMLS65 C0281361

Summaries for Pancreas Adenocarcinoma

About this section
Disease Ontology:10 A pancreatic carcinoma that derives from epithelial cells of glandular origin.

MalaCards based summary: Pancreas Adenocarcinoma, also known as adenocarcinoma of the pancreas, is related to pancreatic cancer and breast cancer. An important gene associated with Pancreas Adenocarcinoma is SMAD4 (SMAD Family Member 4), and among its related pathways are Bisphosphonate Pathway, Pharmacodynamics and MNAR-PELP1 and Estrogen Receptor Interaction. Affiliated tissues include pancreas, liver and lung, and related mouse phenotypes are pigmentation and limbs/digits/tail.

Related Diseases for Pancreas Adenocarcinoma

About this section

Diseases related to Pancreas Adenocarcinoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50)    (show all 188)
idRelated DiseaseScoreTop Affiliating Genes
1pancreatic cancer31.8CDH1, CDKN2A, EGFR, TP53
2breast cancer28.8AKT1, BRCA2, CDH1, EGFR, HRAS, KRAS
3pancreatic ductal adenocarcinoma27.4AKR7A3, AKT1, ANXA8L1, BHLHA15, BRCA2, CDH1
4melanocytic nevus syndrome, congenital, somatic10.5HRAS, NRAS
5spinal cord astrocytoma10.5CDKN2A, TP53
6myh9-related disorders10.5KRAS, SMAD4, TP53
7tetrasomy 12p10.5HRAS, KRAS, NRAS
8spindle cell carcinoma10.5CDH1, TP53
9sigmoid disease10.5HRAS, KRAS, NRAS
10cryptosporidiosis-chronic cholangitis-liver disease syndrome10.5EGFR, KRAS
11diabetic encephalopathy10.5HRAS, KRAS, NRAS
12epidermal nevus, somatic10.5HRAS, KRAS, NRAS
13chronic inflammatory demyelinating polyradiculoneuropathy10.5HRAS, KRAS, NRAS
14schimmelpenning-feuerstein-mims syndrome, somatic mosaic10.5HRAS, KRAS, NRAS
15mucosal melanoma10.5HRAS, KRAS, NRAS
16precursor lymphoblastic lymphoma/leukemia10.5HRAS, KRAS, NRAS
17ovarian serous cystadenocarcinoma10.5HRAS, KRAS, NRAS
18myelofibrosis10.5HRAS, KRAS, NRAS
19neuromuscular disease10.5HRAS, KRAS, NRAS
20ovarian mucinous adenocarcinoma10.5HRAS, KRAS, NRAS
21bicervical bicornuate uterus and blind hemivagina10.5EGFR, KRAS
22intracystic papillary adenoma10.5HRAS, KRAS, TP53
23pneumonic plague10.5HRAS, KRAS, NRAS
24small intestine leiomyoma10.5HRAS, KRAS, NRAS
25malignant fibroxanthoma10.5HRAS, KRAS, NRAS
26serous surface papilloma10.5HRAS, KRAS, NRAS
27corticosterone methyloxidase deficiency10.5HRAS, KRAS, NRAS
28gastrointestinal carcinoma10.5CDKN2A, KRAS, NRAS
29splenogonadal fusion limb defects micrognatia10.5CDKN2A, HRAS, TP53
30gallbladder leiomyosarcoma10.5HRAS, KRAS, NRAS
31lymphatic system disease10.4EGFR, TP53
32diffuse idiopathic pulmonary neuroendocrine cell hyperplasia10.4CDH1, ERCC1, KRAS
33deep leiomyoma10.4CDKN2A, TP53
34pancreatic foamy gland adenocarcinoma10.4MUC1, SMAD4, TP53
35brachydactyly, type e210.4KRAS, NRAS
36hypogonadotropic hypogonadism-frontoparietal alopecia syndrome10.4EGFR, TP53
37intracranial sinus thrombosis10.4CDH1, KRAS, TP53
38basophilic carcinoma10.4CDKN2A, MUC4, TP53
39pancreas sarcoma10.4MUC1, SMAD4, TP53
40pancreatic acinar cell adenocarcinoma10.4
41middle ear squamous cell carcinoma10.4AKT1, CDKN2A, TP53
42malignant giant cell tumor of soft parts10.4HRAS, KRAS, NRAS, SMAD4
43molluscum contagiosum10.4CDKN2A, HRAS, TP53
44common variable immunodeficiency10.4HRAS, KRAS, TP53
45noonan syndrome 710.4HRAS, KRAS, NRAS
46basaloid squamous cell carcinoma10.4CDKN2A, TP53
47mitral valve stenosis10.4BRCA2, CDKN2A, NRAS
48primary thrombocytopenia10.4CDKN2A, NRAS, TP53
49mucinous stomach adenocarcinoma10.4HRAS, KRAS, NRAS, TP53
50head and neck carcinoma10.4HRAS, KRAS, NRAS, TP53

Graphical network of the top 20 diseases related to Pancreas Adenocarcinoma:



Diseases related to pancreas adenocarcinoma

Symptoms for Pancreas Adenocarcinoma

About this section

Drugs & Therapeutics for Pancreas Adenocarcinoma

About this section

FDA approved drugs:

id Drug Name Active Ingredient(s)15 Company Approval Date
1
Abraxane15 41 PACLITAXEL Celgene October 2012
FDA Label: Abraxane
Disease/s that Drug Treats:non-small cell lung cancer
Indications and Usage:15 ABRAXANE is a microtubule inhibitor indicated for the treatment of: Metastatic breast cancer, after failure of combination chemotherapyfor metastatic disease or relapse within 6 months of adjuvantchemotherapy. Prior therapy should have included an anthracyclineunless clinically contraindicated. (1.1) Locally advanced or metastatic non-small cell lung cancer (NSCLC),as first-line treatment in combination with carboplatin, in patients whoare not candidates for curative surgery or radiation therapy. (1.2) Metastatic adenocarcinoma of the pancreas as first-line treatment, incombination with gemcitabine. (1.3)
DrugBank Targets:13 1. Apoptosis regulator Bcl-2;;2. Tubulin beta-1 chain;;3. Nuclear receptor subfamily 1 group I member 2;;4. Microtubule-associated protein 4;;5. Microtubule-associated protein 2; ;6. Microtubule-associated protein tau
Mechanism of Action:15 
Target: microtubule
Action: inhibitor
FDA: ABRAXANE is a microtubule inhibitor that promotes the assembly of microtubules from tubulin dimers and stabilizes microtubulesby preventing depolymerization. This stability results in the inhibition of the normal dynamic reorganization of the microtubulenetwork that is essential for vital interphase and mitotic cellular functions. Paclitaxel induces abnormal arrays or “bundles” ofmicrotubules throughout the cell cycle and multiple asters of microtubules during mitosis.
2
Gemzar15 41 GEMCITABINE HYDROCHLORIDE Eli Lilly May 1996
FDA Label: Gemzar
Disease/s that Drug Treats:pancreatic cancer/Lung cancer
Indications and Usage:15 Gemzar® is a nucleoside metabolic inhibitor indicated: in combination with carboplatin, for the treatment of advanced ovariancancer that has relapsed at least 6 months after completion of platinumbasedtherapy (1.1) in combination with paclitaxel, for first-line treatment of metastaticbreast cancer after failure of prior anthracycline-containing adjuvantchemotherapy, unless anthracyclines were clinically contraindicated(1.2) in combination with cisplatin for the treatment of non-small cell lungcancer (1.3) as a single agent for the treatment of pancreatic cancer (1.4)
DrugBank Targets:13 1. DNA;2. Ribonucleoside-diphosphate reductase large subunit;3. Thymidylate synthase;4. UMP-CMP kinase
Mechanism of Action:15 
Target: ribonucleotide reductase
Action: inhibitor
FDA: Gemcitabine kills cells undergoing DNA synthesis and blocks the progression of cells through the G1/S-phase boundary.Gemcitabine is metabolized by nucleoside kinases to diphosphate (dFdCDP) and triphosphate (dFdCTP) nucleosides. Gemcitabinediphosphate inhibits ribonucleotide reductase, an enzyme responsible for catalyzing the reactions that generate deoxynucleosidetriphosphates for DNA synthesis, resulting in reductions in deoxynucleotide concentrations, including dCTP. Gemcitabinetriphosphate competes with dCTP for incorporation into DNA. The reduction in the intracellular concentration of dCTP by the actionof the diphosphate enhances the incorporation of gemcitabine triphosphate into DNA (self-potentiation). After the gemcitabinenucleotide is incorporated into DNA, only one additional nucleotide is added to the growing DNA strands, which eventually results inthe initiation of apoptotic cell death.
3
Sutent15 41 SUNITINIB MALATE Pfizer May 2011/ January 2006
FDA Label: Sutent
Disease/s that Drug Treats:pancreatic neuroendocrine tumors/ Kidney Cancer/Gastrointestinal Stromal Tumors
Indications and Usage:15 SUTENT is a kinase inhibitor indicated for the treatment of: Gastrointestinal stromal tumor (GIST) after disease progression on orintolerance to imatinib mesylate. (1.1) Advanced renal cell carcinoma (RCC). (1.2) Progressive, well-differentiated pancreatic neuroendocrine tumors(pNET) in patients with unresectable locally advanced or metastaticdisease. (1.3)
DrugBank Targets:13 1. Platelet-derived growth factor receptor beta;2. Vascular endothelial growth factor receptor 1;3. Mast/stem cell growth factor receptor Kit;4. Vascular endothelial growth factor receptor 2;5. Vascular endothelial growth factor receptor 3;6. Receptor-type tyrosine-protein kinase FLT3;7. Macrophage colony-stimulating factor 1 receptor;8. Platelet-derived growth factor receptor alpha
Mechanism of Action:15 
Target: variety of kinases, platelet-derived growth factor receptors (PDGFRα and PDGFRβ), vascular endothelial growth factorreceptors (VEGFR1, VEGFR2 and VEGFR3), stem cell factor receptor (KIT), Fms-like tyrosine kinase-3(FLT3), colony stimulating factor receptor Type 1 (CSF-1R), and the glial cell-line derived neurotrophic factorreceptor (RET)
Action: inhibitor
FDA: Sunitinib is a small molecule that inhibits multiple receptor tyrosine kinases (RTKs), some of which areimplicated in tumor growth, pathologic angiogenesis, and metastatic progression of cancer. Sunitinib wasevaluated for its inhibitory activity against a variety of kinases (>80 kinases) and was identified as an inhibitorof platelet-derived growth factor receptors (PDGFRα and PDGFRβ), vascular endothelial growth factorreceptors (VEGFR1, VEGFR2 and VEGFR3), stem cell factor receptor (KIT), Fms-like tyrosine kinase-3(FLT3), colony stimulating factor receptor Type 1 (CSF-1R), and the glial cell-line derived neurotrophic factorreceptor (RET). Sunitinib inhibition of the activity of these RTKs has been demonstrated in biochemical andcellular assays, and inhibition of function has been demonstrated in cell proliferation assays. The primarymetabolite exhibits similar potency compared to sunitinib in biochemical and cellular assays.Sunitinib inhibited the phosphorylation of multiple RTKs (PDGFR, VEGFR2, KIT) in tumor xenograftsexpressing RTK targets in vivo and demonstrated inhibition of tumor growth or tumor regression and/orinhibited metastases in some experimental models of cancer. Sunitinib demonstrated the ability to inhibitgrowth of tumor cells expressing dysregulated target RTKs (PDGFR, RET, or KIT) in vitro and to inhibitPDGFR- and VEGFR2-dependent tumor angiogenesis in vivo.
4
Abraxane15 PACLITAXEL Celgene October 2012
FDA Label: Abraxane
Disease/s that Drug Treats:non-small cell lung cancer
Indications and Usage:15 ABRAXANE is a microtubule inhibitor indicated for the treatment of: * Metastatic breast cancer, after failure of combination chemotherapy for metastatic disease or relapse within 6 months of adjuvant chemotherapy. Prior therapy should have included an anthracycline unless clinically contraindicated. (1.1) * Locally advanced or metastatic non-small cell lung cancer (NSCLC), as first-line treatment in combination with carboplatin, in patients who are not candidates for curative surgery or radiation therapy. (1.2) * Metastatic adenocarcinoma of the pancreas as first-line treatment, in combination with gemcitabine. (1.3)
DrugBank Targets:13 Apoptosis regulator Bcl-2|Tubulin beta-1 chain|Nuclear receptor subfamily 1 group I member 2|Microtubule-associated protein 4|Microtubule-associated protein 2|Microtubule-associated protein tau|
Mechanism of Action:15 
Target: microtubule
Action: inhibitor
FDA: ABRAXANE is a microtubule inhibitor that promotes the assembly of microtubules from tubulin dimers and stabilizes microtubules by preventing depolymerization. This stability results in the inhibition of the normal dynamic reorganization of the microtubule network that is essential for vital interphase and mitotic cellular functions. Paclitaxel induces abnormal arrays or “bundles” of microtubules throughout the cell cycle and multiple asters of microtubules during mitosis.

Drugs for Pancreas Adenocarcinoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50)    (show all 409)
idNameStatusPhaseClinical TrialsCas NumberPubChem Id
1
MeperidineapprovedPhase 46557-42-14058
Synonyms:
1-Methyl-4-phenyl-4-piperidinecarboxylic acid ethyl ester
1-Methyl-4-phenyl-piperidin-4-carbon-saeure-aethylester
1-Methyl-4-phenyl-piperidin-4-carbon-saeure-aethylester [German]
1-Methyl-4-phenylisonipecotic acid, ethyl ester
1-Methyl-4-phenylpiperidine-4-carboxylic acid ethyl ester
4-Carbethoxy-1-methyl-4-phenylpiperidine
4-Piperidinecarboxylic acid, 1-methyl-4-phenyl-, ethyl ester
50-13-5 (hydrochloride)
57-42-1
610593_ALDRICH
610593_FLUKA
AC1L1HBJ
C07128
CHEBI:122528
CHEMBL607
CID4058
D008614
D08343
DB00454
DEA No. 9230
Demarol
Demerol
DivK1c_000983
Dolcontral
Dolosal
Dolsin
EINECS 200-329-1
Ethyl 1-methyl-4-phenylisonipecotate
Ethyl 1-methyl-4-phenylpiperidine-4-carboxylate
HSDB 3116
IDI1_000983
Isonipecain
Isonipecaine
Isonipecaïne
Isonipecotic acid, 1-methyl-4-phenyl-, ethyl ester
KBio1_000983
L000908
LS-85121
 
Lidol
Lydol
Meperidine
Meperidine Hydrochloride
Meperidine hydrochloride
Meperidine solution
Meperidol
Methyl phenylpiperidine carbonic acid ethyl ester
MolPort-001-785-564
N-Methyl-4-phenyl-4-carbethoxypiperidine
NINDS_000983
Nemerol
Operidine EPJ I
Operidine EPJ-I
Pethanol
Pethidin
Pethidine
Pethidine (INN)
Pethidine DBL
Pethidine DBL (TN)
Pethidine dbl
Pethidine hydrochloride
Pethidineter
Pethidinum
Pethidinum [INN-Latin]
Petidina
Petidina [INN-Spanish]
Petydyna
Petydyna [Polish]
Phetidine
Piperosal
Pipersal
Péthidine
Sauteralgyl
Spasmedal
Spasmodolin
UNII-9E338QE28F
YIsonipecotic acid, 1-methyl-4-phenyl-, ethyl ester (8CI)
meperidine
2
PancrelipaseapprovedPhase 4, Phase 3, Phase 2, Phase 1, Phase 088053608-75-6
Synonyms:
1,4-alpha-D- glucan glucanohydrolase
Creon
PA
Pancreatic alpha-amylase precursor
Pancreaze
 
Pancrelipase
Pertzye
Polocaine-mpf
Ultresa
Viokace
Zenpep
3
EtomidateapprovedPhase 45733125-97-236339, 667484
Synonyms:
(+)-Ethyl 1-(alpha-methylbenzyl)imidazole-5-carboxylate
(+)-Etomidate
(+)-ethyl 1-(α-methylbenzyl)imidazole-5-carboxylate
(+)-etomidate
(R)-(+)-1-(alpha-Methylbenzyl)imidazole-5-carboxylic acid ethyl ester
(R)-1-(1-phenylethyl)-1H-imidazole-5-carboxylic acid ethyl ester
(d)-Etomidate
1-(1-Phenylethyl)-1H-imidazole-5-carboxylic acid ethyl ester
1-(1-Phenylethyl)-imidazole-5-carboxylic acid, ethyl ester
1-(alpha-Methylbenzyl)-1H-imidazole-5-carboxylic acid ethyl ester
15301-65-2
1H-Imidazole-5-carboxylic acid, 1-((1R)-1-phenylethyl)-, ethyl ester
3-((R)-1-Phenyl-ethyl)-3H-imidazole-4-carboxylic acid ethyl ester
3-(1-Phenyl-ethyl)-3H-imidazole-4-carboxylic acid ethyl ester
33125-97-2
AC-5898
AC1L1VLF
AC1Q34BV
AC1Q64LP
AKOS000548952
Absele
Amidate
Amidate (TN)
Amidate (pharmaceutical)
Amidate, Etomidate
BAS 01947657
BRN 0665833
C07522
C14H16N2O2
CHEBI:129025
CHEMBL23731
CID36339
CPD000010931
D-Etomidate
D005045
D00548
 
DB00292
EINECS 251-385-9
Ethnor
Ethomidate
Ethyl 1-(1-phenylethyl)-1H-imidazole-5-carboxylate
Etomidate
Etomidate (USAN/INN)
Etomidate [USAN:BAN:INN]
Etomidato
Etomidato [INN-Spanish]
Etomidatum
Etomidatum [INN-Latin]
Etomidic acid
HMS1571A04
HMS1612G10
HMS2093P17
Hypnomidate
LS-78232
MLS000034952
MLS001240191
MolPort-000-917-569
Prestwick0_001041
Prestwick1_001041
Prestwick2_001041
R 16659
R 26490
R-(+)-Ethyl 1-(1-phenylethyl)-1H-imidazole-5-carboxylate
R-26490
R26490
Radenarcon
Radenarkon
S1329_Selleck
SAM002548930
SBB066197
SMR000010931
SPBio_002901
UNII-Z22628B598
ethyl 3-(1-phenylethyl)imidazole-4-carboxylate
4
Oxaliplatinapproved, investigationalPhase 4, Phase 3, Phase 2, Phase 1, Phase 0132261825-94-35310940, 9887054, 6857599, 43805, 6857599, 9887054
Synonyms:
CHEMBL1201055
CID9887054
D01790
DACPLAT
Diaminocyclohexane Oxalatoplatinum
Eloxatin
Eloxatin (TN)
Elplat
Foloxatine
L-OHP
 
Oxalatoplatin
Oxalatoplatinum
Oxaliplatin
Oxaliplatin (JAN/USAN/INN)
Oxaliplatin [Usan:Inn:Ban]
Oxaliplatino [Spanish]
Oxaliplatinum [Latin]
Oxaloplatine [French]
Oxaloplatino [Spanish]
Transplatin
oxaliplatin
5
Midazolamapproved, illicitPhase 463559467-70-84192
Synonyms:
4H-Imidazo[1,5-a][1,4]benzodiazepine, 8-chloro-6-(2-fluoro-phenyl)-1-methyl-, (Z)-2-butenedioate
59467-70-8
8-Chlor-6-(2-fluorphenyl)-1-methyl-4H-imidazo(1,5-a)(1,4)benzodiazepin
8-Chloro-6-(2-fluorophenyl)-1-methyl-4H-imidazo[1,5-a][1,4]benzodiazepine
8-Chloro-6-(2-fluorophenyl)-1-methyl-4H-imidazo[1,5a][1,4]benzodiazepine hydrochloride
8-Chloro-6-(O-fluorophenyl)-1-methyl-4H-imidazo[1,5-a][1,4]-benzodiazepine
8-Chloro-6-(o-fluorophenyl)-1-methyl-4H-imidazo(1,5-a)(1,4)benzodiazepine
AC-18749
AC1L1HMA
BIDD:GT0647
BRN 0625572
Buccolam
C07524
C18H13ClFN3
CHEMBL655
CID4192
D00550
DB00683
DEA No. 2884
Dazolam
Dea No. 2884
Dormicum
 
Dormicum (TN)
EINECS 261-774-5
LS-77780
Midanium
Midazolam
Midazolam (JAN/INN)
Midazolam Base
Midazolam Hcl
Midazolam Hydrochloride
Midazolam [INN:BAN:JAN]
Midazolamum
Midazolamum [INN-Latin]
Midosed
MolPort-003-849-219
NCGC00168254-01
Ro 21-3981
TL8003787
UC429_SIGMA
UNII-R60L0SM5BC
Versed
ZINC00001732
midazolam
nchembio747-comp32
6
GemcitabineapprovedPhase 4, Phase 3, Phase 2, Phase 1, Phase 0188195058-81-460750
Synonyms:
103882-84-4
122111-03-9
2',2'-DiF-dC
2',2'-Difluoro-2'-deoxycytidine
2',2'-Difluorodeoxycytidine
2'-Deoxy-.beta.-D-2',2'-difluorocytidine
2'-Deoxy-2',2'-difluorocytidine
4-Amino-1-[(2R,4R,5R)-3,3-difluoro-4-hydroxy-5-(hydroxymethyl)oxolan-2-yl]pyrimidin-2-one
4-Amino-1-[3,3-difluoro-4-hydroxy-5-(hydroxymethyl) tetrahydrofuran-2-yl]-1H-pyrimidin-2-one
4-amino-1-((2R,4R,5R)-3,3-Difluoro-4-hydroxy-5-(hydroxymethyl)-tetrahydrofuran-2-yl)pyrimidin-2(1H)-one
4-amino-1-((2R,4R,5R)-3,3-difluoro-4-hydroxy-5-(hydroxymethyl)-tetrahydrofuran-2-yl)pyrimidin-2(1H)-one
95058-81-4
AB1004842
AC1L1TUQ
C07650
CCRIS 8984
CHEBI:175901
CHEMBL888
CID60750
Cytidine, 2'-deoxy-2',2'-difluoro-2'-Deoxy-.beta.-D-2',2'-difluorocytidine
D02368
DB00441
DDFC
DFDC
DFdC
DFdCyd
Folfugem
GEO
Gamcitabine
GemLip
Gemcel
 
Gemcin
Gemcitabin
Gemcitabina
Gemcitabina [INN-Spanish]
Gemcitabine
Gemcitabine (USAN/INN)
Gemcitabine HCl
Gemcitabine Hydrochloride
Gemcitabine hydrochloride
Gemcitabine stereoisomer
Gemcitabinum
Gemcitabinum [INN-Latin]
Gemtro
Gemzar
Gemzar (hydrochloride)
HMS2089P10
HSDB 7567
Inno-D07001
LS-59139
LY 188011
LY-188011
LY188011
NCGC00168784-01
NChemBio.2007.10-comp25
NSC 613327
NSC613327
TL8005979
UNII-B76N6SBZ8R
ZINC18279854
Zefei
gemcitabine
nchembio.573-comp7
nchembio.90-comp2
7
Lansoprazoleapproved, investigationalPhase 4198103577-45-33883
Synonyms:
103577-45-3
2-(((3-Methyl-4-(2,2,2-trifluoroethoxy)-2-pyridinyl)methyl)sulfinyl)-1H-benzimidazole
2-(((3-Methyl-4-(2,2,2-trifluoroethoxy)-2-pyridyl)methyl)sulfinyl)benzimidazole
2-(((3-methyl-4-(2,2,2-trifluoroethoxy)-2-pyridyl)methyl)sulfinyl)-1H-benzimidazole
2-({[3-methyl-4-(2,2,2-trifluoroethoxy)pyridin-2-yl]methyl}sulfinyl)-1H-benzimidazole
2-[({3-methyl-4-[(2,2,2-trifluoroethyl)oxy]pyridin-2-yl}methyl)sulfinyl]-1H-benzimidazole
2-[[3-methyl-4-(2,2,2-trifluoroethoxy)pyridin-2-yl]methylsulfinyl]-1H-benzimidazole
2-[[[3-methyl-4-(2,2,2-trifluoroethoxy)-2-pyridyl] methyl] sulfinyl] benzimidazole
2-[[[3-methyl-4-(2,2,2-trifluroethoxy)-2-pyridyl]methyl]sulfinyl]benzimidazole
A 65006
A-65006
AB00052388
ABT-006
AC1L1GX8
AG 1749
AG-1749
Abbot Brand of Lansoprazole
Agopton
Almirall Brand of Lansoprazole
Amarin
Aprazol
BIDD:GT0006
BPBio1_001194
BRD-A49172652-001-05-7
BRN 4333393
BSPBio_001084
BSPBio_001830
Bamalite
Bio-0824
Biuret
Biuret Gr
Biuret Reagent
Biuret Reagent Solution
Blason
C058687
C16H14F3N3O2S
CAS-103577-45-3
CG-4801
CHEBI:6375
CHEMBL480
CID3883
CPD000058469
Careone Lansoprazole
Compraz
D00355
DB00448
Dakar
Dg Health Lansoprazole
DivK1c_000920
EU-0100709
Equaline Lansoprazole
Equate Lansoprazole Delayed Release
Exchange Select Lansoprazole
FT-0082011
Good Neighbor Pharmacy Lansoprazole
Good Sense Lansoprazole
HMS1571G06
HMS1922M04
HMS2052F05
HMS2093M07
HMS502N22
HSDB 7204
Health Mart Lansoprazole
Healthy Accents Lansoprazole
Heartburn Relief 24 Hour
Hoechst Brand of Lansoprazole
Hormona Brand of Lansoprazole
I06-0018
IDI1_000920
Ilsatec
KBio1_000920
KBio2_002060
KBio2_004628
KBio2_007196
KBio3_001330
KBioGR_001491
KBioSS_002060
Ketian
Kirkland Signature Lansoprazole Delayed Release
L 8533
L8533_SIGMA
LS-33080
Lancid
Lanfast
Lanproton
Lansopep
Lansophed
Lansoprazol
Lansoprazol [INN-Spanish]
Lansoprazole
Lansoprazole (JAN/USP/INN)
Lansoprazole Heartburn Relief 24 Hour
Lansoprazole [USAN:BAN:INN]
Lansoprazole [Usan:Ban:Inn]
Lansoprazolum
Lansoprazolum [INN-Latin]
Lansox
 
Lanston
Lanz
Lanzo
Lanzol
Lanzol-30
Lanzopral
Lanzor
Lanzul
Lapraz
Lasoprol
Leader Lansoprazole
Lederle Brand of Lansoprazole
Limpidex
Linamarin
Lopac-L-8533
Lopac0_000709
MLS-0003247.0001
MLS000069705
MLS000759405
MLS001074170
Mesactol
MolPort-003-666-508
MolPort-006-394-760
Monolitum
NCGC00015615-01
NCGC00015615-02
NCGC00015615-03
NCGC00015615-06
NCGC00015615-11
NCGC00023826-03
NCGC00023826-04
NCGC00023826-05
NCGC00023826-06
NCGC00023826-07
NINDS_000920
Ogast
Ogastro
Opiren
Preferred Plus Lansoprazole
Prestwick0_001072
Prestwick1_001072
Prestwick2_001072
Prestwick3_001072
PrevOnco
Prevacid
Prevacid (TN)
Prevacid 24 HR
Prevacid I.V
Prevacid I.V.
Prevacid Iv
Prevacid SoluTab
Prevacid Solutab
Prevacid, Prevacid NapraPAC, Prevacid SoluTab, Lansoprazole
Prevpac
Prezal
Pro Ulco
Promeco
Promeco Brand of Lansoprazole
Promp
Prosogan
Rugby Heartburn Treatment
S1354_Selleck
SAM001246544
SMR000058469
SPBio_000488
SPBio_002992
SPECTRUM1503926
STK621169
Salvar Brand of Lansoprazole
Shoprite Lansoprazole
Simply Right Lansoprazole
Smart Sense Acid Reducer
Spectrum2_000444
Spectrum3_000295
Spectrum4_000856
Spectrum5_001521
Spectrum_001580
Sunmark Lansoprazole
Suprecid
TAK 390MR
TAK-390MR
TAK390MR
TAP Brand of Lansoprazole
TL8000155
Takeda Brand of Lansoprazole
Takepron
Tecnobio Brand of Lansoprazole
Topcare Lansoprazole
UNII-0K5C5T2QPG
Ulpax
Vinas Brand of Lansoprazole
Well At Walgreens Lansoprazole
Wyeth Brand of Lansoprazole
Zoprol
Zoton
lansoprazole
lansoprazole sulphone
lanzoprazole
8
Capecitabineapproved, investigationalPhase 4, Phase 3, Phase 2, Phase 11220154361-50-960953
Synonyms:
(1-(5-Deoxy-beta-D-ribofuranosyl)-5-fluoro-1,2-dihydro-2-oxo-4-pyrimidinyl)-carbamic acid pentyl ester
154361-50-9
158798-73-3
5'-Deoxy-5-fluoro-N-((pentyloxy)carbonyl)cytidine
5'-deoxy-5-fluoro-N-[(pentyloxy)carbonyl]cytidine
AC1L1U83
AC1Q4KU8
Ambap154361-50-9
C110904
C12650
C15H22FN3O6
CAPE
CAPECITABINE
CHEBI:31348
CHEMBL1773
CID60953
Capecitabin
Capecitabina
Capecitabine
Capecitabine (JAN/USAN/INN)
Capecitabine [USAN]
Capecitabinum
Capecitibine
Capiibine
Carbamic acid, (1-(5-deoxy-beta-D-ribofuranosyl)-5-fluoro-1,2-dihydro-2-oxo-4-pyrimidinyl)-, pentyl ester
Caxeta
 
D01223
DB01101
FT-0082472
HSDB 7656
LS-59070
MolPort-005-938-254
N(4)-Pentyloxycarbonyl-5'-deoxy-5-fluorocytidine
Pentyl 1-(5-deoxy-beta-D-ribofuranosyl)-5-fluoro-1,2-dihydro-2-oxo-4-pyrimidinecarbamate
Pentyl [1-(5-deoxy-beta-D-ribofuranosyl)-5-fluoro-2-oxo-1,2-dihydropyrimidin-4-yl]carbamate
R-340
R340
RG-340
Ro 09-1978
Ro 09-1978/000
Ro-09-1978
Ro-09-1978/000
S1156_Selleck
UNII-6804DJ8Z9U
Xabine
Xeloda
Xeloda (TN)
Xeloda, Captabin, Capecitabine
ZINC03806413
capecitabina
capecitabine
capecitabinum
pentyl N-[1-[(2R,3R,4S,5R)-3,4-dihydroxy-5-methyloxolan-2-yl]-5-fluoro-2-oxopyrimidin-4-yl]carbamate
9
Propofolapproved, investigationalPhase 4, Phase 19312078-54-84943
Synonyms:
2, 6-Diisopropylphenol
2,6 Diisopropylphenol
2,6-Bis(1-methylethyl)phenol
2,6-Bis(Isopropyl)-phenol
2,6-DIISOPROPYLPHENOL
2,6-Diisopropyl phenol
2,6-Diisopropylphenol
2,6-bis(1-methylethyl)-phenol
2,6-di(propan-2-yl)phenol
2078-54-8
28449-97-0
4-06-00-03435 (Beilstein Handbook Reference)
50356-15-5
AB00513968
AC-2038
AC1L1J9Y
AC1Q1OUI
AI3-26295
AM-149
Abbott Brand of Propofol
Alpha Brand of Propofol
Ampofol
Aquafol
Astra Brand of Propofol
AstraZeneca Brand of Propofol
BIDD:GT0436
BPBio1_000950
BPBio1_000969
BRD-K82255054-001-03-5
BRN 1866484
BSPBio_000862
Biomol-NT_000248
Braun Brand of Propofol
C07523
C12H18O
CAS-2078-54-8
CCRIS 9000
CHEBI:44915
CHEMBL526
CID4943
CPD-11437
CPD000059151
Curamed Brand of Propofol
D00549
D015742
D0617
D126608
D126608_ALDRICH
DB00818
DDS-04F
Diisopropylphenol
Dipravan
Diprivan
Diprivan (TN)
Diprivan Injectable emulsion
Disoprivan
Disoprofol
EINECS 218-206-6
EU-0100437
Fresenius Brand of Propofol
Fresenius Kabi Brand of Propofol
Fresofol
HMS1570L04
HMS2089O21
HMS2094E17
 
HSDB 7123
ICI 35,868
ICI 35868
ICI-35,868
ICI-35868
ICI35,868
ICI35868
InChI=1/C12H18O/c1-8(2)10-6-5-7-11(9(3)4)12(10)13/h5-9,13H,1-4H
Ivofol
Jsp004266
Juste Brand of Propofol
LS-996
Lopac-D126608
Lopac0_000437
MLS001066348
MLS001335999
MLS002454360
MolPort-001-794-517
NCGC00015389-01
NCGC00015389-02
NCGC00015389-04
NCGC00015389-09
NCGC00091538-01
NCGC00091538-02
NCGC00091538-03
NCGC00091538-04
NCGC00091538-05
NCGC00091538-06
NSC 5105
NSC5105
PFL
Parnell Brand of Propofol
Pisa Brand of Propofol
Prestwick0_000931
Prestwick1_000931
Prestwick2_000931
Prestwick3_000931
Propofol
Propofol (JAN/USAN/INN)
Propofol Abbott
Propofol Fresenius
Propofol IDD-D
Propofol MCT
Propofol Rovi
Propofol [USAN:INN:BAN]
Propofol(2,6-Diisopropylphenol)
Propofol-Lipuro
Propofolum
Propofolum [Latin]
Rapinovet
Recofol
Rovi Brand of Propofol
S01-0189
SAM002264610
SMR000059151
SPBio_003031
SPECTRUM1505022
ST50405911
Schering Brand of Propofol
UNII-YI7VU623SF
W505102_ALDRICH
ZD-0859
ZINC00968303
Zeneca Brand of Propofol
ghl.PD_Mitscher_leg0.558
nchembio.552-comp7
propofol
10
Sunitinibapproved, investigationalPhase 4, Phase 3, Phase 2, Phase 1486341031-54-7, 557795-19-45329102
Synonyms:
(2S)-2-hydroxybutanedioic acid
1H-Pyrrole-3-carboxamide, N-(2-(diethylamino)ethyl)-5-((Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl)-2,4-dimethyl-, (2S)-hydroxybutanedioate (1:1)
1H-Pyrrole-3-carboxamide, N-(2-(diethylamino)ethyl)-5-((Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl)-2,4-dimethyl-, (2S)-hydroxybutanedioate (1:1)
326914-13-0
341031-54-7
5-(5-FLUORO-2-OXO-1,2-DIHYDRO-INDOL-3-YLIDENEMETHYL)-2,4-DIMETHYL-1H-PYRROLE-3-CARBOXYLIC ACID (2-DIETHYLAMINO-ETHYL)-AMIDE
557795-19-4
AC1NS62J
AC1O5CMQ
AKOS005145765
Butanedioic acid, hydroxy-, (2S)-, compd. with N-(2-(diethylamino)ethyl)-5-((Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl)-2,4-dimethyl-1H-pyrrole-3-carboxamide (1:1)
CHEBI:38940
CHEBI:550864
CHEMBL1567
CHEMBL535
CID5329102
CID6456015
D06402
D08552
DB01268
DB07417
EN002687
FT-0083555
FT-0083556
I01-1229
K00588a
KS-5022
LS-186078
LS-187023
LS-187648
MolPort-003-986-763
N-(2-(Diethylamino)ethyl)-5-((Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl)-2,4-dimethyl-1H-pyrrole-3-carboxamide (2S)-hydroxybutanedioate
N-(2-diethylaminoethyl)-5-[(Z)-(5-fluoro-2-oxo-1H-indol-3-ylidene)methyl]-2,4-dimethyl-1H-pyrrole-3-carboxamide
N-[2-(diethylamino)ethyl]-5-[(Z)-(5-fluoro-2-oxo-1,2-dihydro-3H-indol-3-ylidene)methyl]-2,4-dimethyl-1H-pyrrole-3-carboxamide
NCGC00164631-01
 
NSC736511
NSC750690
PDGF TK antagonist
PHA-290940AD
PNU-290940AD
S1042_Selleck
ST51053712
SU 011248
SU 11248
SU-010398
SU-011248 L-malate salt
SU-11248
SU-11248 L-malate salt
SU-11248J
SU-12662
SU010398
SU011248
SU011248 L-malate salt
SU11248
Su-011248
Sunitanib
Sunitinib
Sunitinib (INN)
Sunitinib (free base)
Sunitinib Malate
Sunitinib malate
Sunitinib malate (JAN/USAN)
Sunitinib malate [USAN]
Sunitinibum
Sutent
Sutent (TN)
Sutent, SU-11248
TL8002546
UNII-LVX8N1UT73
UNII-V99T50803M
sunitinib
sunitinibum
11
Secretinapproved, investigationalPhase 4, Phase 1, Phase 2, Phase 029108153-74-8
Synonyms:
108153-74-8
1393-25-5
67307-60-2 (citrate (salt))
9002-77-1
EINECS 215-733-3
Hormone of the duodenal mucosa that activates pancreatic secretion and lowers the blood sugar level
Human secretin
I06-1828
L-Histidyl-L-seryl-L-alpha-aspartylglycyl-L-threonyl-L-phenylalanyl-L-threonyl-L-seryl-L-alpha-glutamyl-L-leucyl-L-seryl-L-arginyl-L-leucyl-L-arginyl-L-alpha-aspartyl-L-seryl-L-alanyl-L-arginyl-L-leucyl-L-glutaminyl-L-arginyl-L-leucyl-L-leucyl-L-glutaminylglycyl-L-leucyl-L-valinamide
L-Histidyl-L-seryl-L-alpha-aspartylglycyl-L-threonyl-L-phenylalanyl-L-threonyl-L-seryl-L-alpha-glutamyl-L-leucyl-L-seryl-L-arginyl-L-leucyl-L-arginyl-L-alpha-glutamylglycyl-L-alanyl-L-arginyl-L-leucyl-L-glutaminyl-L-arginyl-L-leucyl-L-leucyl-L-glutaminylglycyl-L-leucyl-L-valinamide
LS-144747
RG 1068
SECREFLO
SECRETIN
SECRETIN-FERRING
 
SecreFlow
Secrepan
Secretin (human)
Secretin (porcine)
Secretin [INN:BAN:DCF:JAN]
Secretin-Kabi
Secretina
Secretina [INN-Spanish]
Secretine
Secretine [INN-French]
Secretinum
Secretinum [INN-Latin]
Secretolin
UNII-88C55N56UU
UNII-A0426J905J
Vitrum
12
DiazoxideapprovedPhase 421364-98-73019
Synonyms:
2H-1,2, 4-Benzothiadiazine, 7-chloro-3-methyl-, 1,1-dioxide
2H-1,2,4-Benzothiadiazine, 7-chloro-3-methyl-, 1,1-dioxide
364-98-7
7-Chloro-3-methyl-1lambda~4~,2,4-benzothiadiazin-1-ol 1-oxide
7-Chloro-3-methyl-2H-1,2,4-benzothiadiazine 1,1-dioxide
7-Cloro-3-metil-2H-1,2,4-benzotiodiazina-1,1-diossido
7-Cloro-3-metil-2H-1,2,4-benzotiodiazina-1,1-diossido [Italian]
7-chloro-3-methyl-4H-1
AC1L1EZN
Aroglycem
BPBio1_000016
BRD-K73109821-001-05-2
BSPBio_000014
BSPBio_001307
BSPBio_002290
Bio1_000036
Bio1_000525
Bio1_001014
Bio2_000027
Bio2_000507
C06949
C8H7ClN2O2S
CAS-364-98-7
CBiol_001750
CHEBI:4495
CHEMBL181
CID3019
CPD000058392
D 9035
D00294
D003981
D9035_SIGMA
DB01119
Diazossido
Diazossido [DCIT]
Diazossido [Italian]
Diazoxide
Diazoxide (JAN/USP/INN)
Diazoxide [USAN:INN:BAN]
Diazoxido
Diazoxido [INN-Spanish]
Diazoxidum
Diazoxidum [INN-Latin]
Dizoxide
EINECS 206-668-1
EU-0100404
Eudemine
HMS1361B09
HMS1568A16
HMS1791B09
HMS1922L22
HMS1989B09
HMS2051P20
HMS2089L04
HMS2093N12
Hyperstat
Hyperstat (TN)
Hypertonalum
I06-2041
 
IDI1_033777
KBio2_000027
KBio2_002595
KBio2_005163
KBio3_000053
KBio3_000054
KBio3_001510
KBioGR_000027
KBioGR_001776
KBioSS_000027
LS-40410
Lopac-D-9035
Lopac0_000404
MLS000028459
MLS001076071
MolPort-003-666-772
MolPort-003-941-186
Mutabase
NCGC00015380-01
NCGC00015380-02
NCGC00015380-03
NCGC00015380-05
NCGC00015380-12
NCGC00024907-01
NCGC00024907-02
NCGC00024907-03
NCGC00024907-04
NCGC00024907-05
NCGC00024907-06
NCGC00024907-07
NCGC00024907-08
NSC 64198
NSC 76130
NSC-64198
NSC64198
NSC76130
Prestwick0_000087
Prestwick1_000087
Prestwick2_000087
Prestwick3_000087
Prestwick_163
Proglicem
Proglycem
SAM001246872
SMR000058392
SPBio_001953
SPECTRUM2300206
SRG 95213
SRG-95213
Sch 6783
Sch-6783
Spectrum3_000735
Spectrum4_001248
Tocris-0964
UNII-O5CB12L4FN
VU0239714-6
ZINC03872277
diazoxide
nchembio.150-comp49
nchembio.476-comp10
13
DesfluraneapprovedPhase 412557041-67-542113
Synonyms:
(+-)-2-Difluoromethyl 1,2,2,2-tetrafluoroethyl ether
1,1,1,2-Tetrafluoro-2-(difluoromethoxy)ethane
1,1,1,2-tetrafluoro-2-(difluoromethoxy)ethane
2-(difluoromethoxy)-1,1,1,2-tetrafluoroethane
57041-67-5
AC1L274J
AC1Q4ICY
C07519
C3H2F6O
CHEBI:4445
CHEMBL1200733
CID42113
D00546
DB01189
DESFLURANE
Desflurane
 
Desflurane (JAN/USP/INN)
Desflurane [USAN:INN]
Desflurano
Desflurano [INN-Spanish]
Desfluranum
Desfluranum [INN-Latin]
Difluoromethyl 1,2,2,2-tetrafluoroethyl ether
I 653
I-653
I653
LS-65505
MolPort-001-776-387
PC6781E
Suprane
Suprane (TN)
UNII-CRS35BZ94Q
difluoromethyl 1,2,2,2-tetrafluoroethyl ether
r-e 236ea1
14Hormone AntagonistsPhase 4, Phase 3, Phase 2, Phase 1, Phase 010002
15HormonesPhase 4, Phase 3, Phase 2, Phase 1, Phase 011748
16pancreatinPhase 4, Phase 3, Phase 2, Phase 1, Phase 0880
17Fluorodeoxyglucose F18Phase 4, Phase 2, Phase 1356
18Antiviral AgentsPhase 4, Phase 3, Phase 2, Phase 1, Phase 08071
19Hormones, Hormone Substitutes, and Hormone AntagonistsPhase 4, Phase 3, Phase 2, Phase 1, Phase 09988
20Immunosuppressive AgentsPhase 4, Phase 3, Phase 2, Phase 1, Phase 010422
21Insulin, Globin ZincPhase 4, Phase 1, Phase 24278
22Vasodilator AgentsPhase 4, Phase 2, Phase 12926
23AntimetabolitesPhase 4, Phase 3, Phase 2, Phase 1, Phase 09454
24insulinPhase 4, Phase 1, Phase 24278
25pancreatic polypeptidePhase 4, Phase 3, Phase 2, Phase 120
26
Proton pump inhibitorsPhase 4, Phase 3, Phase 2958
Synonyms:
 
PPIs
27Angiogenesis InhibitorsPhase 4, Phase 3, Phase 2, Phase 13688
28Angiogenesis Modulating AgentsPhase 4, Phase 3, Phase 2, Phase 13611
29Immunologic FactorsPhase 4, Phase 3, Phase 2, Phase 1, Phase 018483
30Liver ExtractsPhase 4, Phase 3, Phase 2, Phase 1, Phase 03572
31AnestheticsPhase 4, Phase 3, Phase 2, Phase 17385
32Analgesics, OpioidPhase 4, Phase 32304
33Anesthetics, GeneralPhase 4, Phase 32274
34Anesthetics, IntravenousPhase 4, Phase 31943
35Anti-Anxiety AgentsPhase 4, Phase 31529
36Gastrointestinal AgentsPhase 4, Phase 3, Phase 1, Phase 2, Phase 06401
37Phase 4, Phase 2, Phase 1
38Antimetabolites, AntineoplasticPhase 4, Phase 3, Phase 2, Phase 1, Phase 05770
39Anti-Infective AgentsPhase 4, Phase 3, Phase 2, Phase 1, Phase 017220
40Anti-Infective Agents, LocalPhase 4, Phase 1984
41Central Nervous System DepressantsPhase 4, Phase 3, Phase 110016
42GABA ModulatorsPhase 4657
43AnalgesicsPhase 4, Phase 3, Phase 1, Phase 29358
44Tranquilizing AgentsPhase 4, Phase 33597
45
DexlansoprazolePhase 4198138530-94-6, 103577-45-39578005
Synonyms:
138530-94-6
CHEMBL1201863
CID9578005
D08903
Dexlansoprazole (INN/USAN)
KS-1075
 
Kapidex
MolPort-002-885-834
T 168390
TAK 390
UNII-UYE4T5I70X
ZINC00599734
dexlansoprazole
46Hypnotics and SedativesPhase 42032
47AntacidsPhase 4, Phase 3, Phase 21453
48Psychotropic DrugsPhase 4, Phase 3, Phase 15501
49NarcoticsPhase 4, Phase 32709
50Neurotransmitter AgentsPhase 4, Phase 3, Phase 2, Phase 114795

Interventional clinical trials:

(show top 50)    (show all 951)
idNameStatusNCT IDPhase
1Pharmacokinetic Study of Adjuvant Capecitabine After Resection of Pancreatic AdenocarcinomaCompletedNCT00854477Phase 4
2Endoscopic Ultrasound-guided Celiac Plexus Neurolysis (EUS-CPN)With Alcohol in Unresectable Pancreatic Cancer: a Pilot StudyCompletedNCT00578279Phase 4
3Etomidate vs. Midazolam for Sedation During ERCPCompletedNCT02027311Phase 4
4Influence of an Oral Nutritional Supplement Rich in Omega-3 Fatty Acids on Functional State and Quality of Life in Malnourished Patients With Gastroenterological TumorsCompletedNCT00168987Phase 4
5Treatment of Zollinger-Ellison Syndrome With PrevacidCompletedNCT00204373Phase 4
6Efficacy of Secretin MRCP in the Diagnosis and Follow up of Auto Immune PancreatitisRecruitingNCT01845467Phase 4
7Lipidomics, Proteomics, Micro RNAs and Volatile Organic CompoundsRecruitingNCT02531607Phase 4
8Relationship Between Platinum Levels in the Blood and Neurotoxicity in Patients Who Are Receiving Oxaliplatin for Gastrointestinal CancerRecruitingNCT00274885Phase 4
9Nonfunctional Pancreatic NET and PET ImagingRecruitingNCT02621541Phase 4
10Uncovered Self-expandable Metal Stent Versus Double Layer Plastic Stent for Malignant Hilar StrictureRecruitingNCT01125865Phase 4
11A Dose Escalation Safety Study of Locally-Delivered Gemcitabine in Pancreatic CancerActive, not recruitingNCT02237157Phase 4
12Clinical Effectiveness of Serum Chromogranin A Levels on Diagnostic of Pancreatic Neuroendocrine TumorsActive, not recruitingNCT02759718Phase 4
13A Study Of The Efficacy And Safety Of Sunitinib In Patients With Advanced Well-Differentiated Pancreatic Neuroendocrine TumorsActive, not recruitingNCT01525550Phase 4
14Early Oral Versus Enteral Nutrition After PancreatoduodenectomyActive, not recruitingNCT01642875Phase 4
15Disease-Specific Questionnaire in Assessing Quality of Life in Patients With Gastrointestinal-Related Neuroendocrine TumorsActive, not recruitingNCT00454376Phase 4
16Pasireotide Treatment for Neuroendocrine TumorEnrolling by invitationNCT02779257Phase 4
17CTC Pancreatic AdenocarcinomaNot yet recruitingNCT02335151Phase 4
18Prevention of Upper Gastrointestinal Hemorrhage Using Albis® in the Patients of Locally Advanced Pancreatic Cancer Who Underwent Concurrent ChemoradiotherapyNot yet recruitingNCT02570529Phase 4
19Pancreatic Enzyme Suppletion in Pancreatic CancerWithdrawnNCT01401387Phase 4
20Phase III Study of ABI-007(Albumin-bound Paclitaxel) Plus Gemcitabine Versus Gemcitabine in Metastatic Adenocarcinoma of the PancreasCompletedNCT00844649Phase 3
21Study of the Efficacy and Safety of Glufosfamide Compared With Best Supportive Care in Metastatic Pancreatic CancerCompletedNCT00099294Phase 3
22Fluorouracil, Gemcitabine, and Radiation Therapy in Treating Patients With Cancer of the PancreasCompletedNCT00003216Phase 3
23Gemcitabine With or Without Capecitabine and/or Radiation Therapy or Gemcitabine With or Without Erlotinib in Treating Patients With Locally Advanced Pancreatic Cancer That Cannot Be Removed by SurgeryCompletedNCT00634725Phase 3
24Gemcitabine or Combination Chemotherapy Followed by Chemoradiation for Stage IB, II, or III Pancreatic CancerCompletedNCT00960284Phase 2, Phase 3
25Irofulven Compared With Fluorouracil in Treating Patients With Pancreatic CancerCompletedNCT00033735Phase 3
26S0205 Gemcitabine w/ or w/o Cetuximab as First-Line Therapy in Locally Advanced Pancreas CancerCompletedNCT00075686Phase 3
27Gemcitabine With or Without Bevacizumab in Treating Patients With Locally Advanced or Metastatic Pancreatic CancerCompletedNCT00088894Phase 3
28Gemcitabine and ON 01910.Na in Previously Untreated Metastatic Pancreatic CancerCompletedNCT01360853Phase 3
29Two Chemotherapy Regimens Compared With Observation in Treating Patients With Completely Resected Pancreatic CancerCompletedNCT00058201Phase 3
30Safety and Efficacy of G17DT Immunogen Combined With Gemcitabine vs. Gemcitabine in the Treatment of Advanced Pancreatic CarcinomaCompletedNCT00044031Phase 3
31Triacetyluridine and Fluorouracil Compared With Gemcitabine in Treating Patients With Unresectable Locally Advanced, or Metastatic Pancreatic CancerCompletedNCT00024427Phase 3
32Gemcitabine With or Without Tipifarnib (R115777) in Treating Patients With Advanced Pancreatic CancerCompletedNCT00005648Phase 3
33Surgery Followed by Radiation Therapy and Chemotherapy in Treating Patients With Cancer of the PancreasCompletedNCT00003049Phase 3
34Fluorouracil With or Without Cisplatin in Treating Patients With Advanced or Metastatic Cancer of the PancreasCompletedNCT00003029Phase 3
35Gemcitabine With or Without Capecitabine in Treating Patients With Advanced Pancreatic CancerCompletedNCT00030732Phase 3
36Gemcitabine With or Without Oxaliplatin in Treating Patients With Locally Advanced or Metastatic Pancreatic CancerCompletedNCT00058149Phase 3
37Gemcitabine and Radiation Therapy Compared With Gemcitabine Alone in Treating Patients Who Have Undergone Surgery for Pancreatic CancerCompletedNCT00064207Phase 2, Phase 3
38Gemcitabine With or Without Erlotinib in Treating Patients With Unresectable Locally Advanced or Metastatic Pancreatic CancerCompletedNCT00026338Phase 3
39Gemcitabine With or Without Radiation Therapy in Treating Patients With Pancreatic CancerCompletedNCT00057876Phase 3
40Combination Chemotherapy in Treating Patients With Metastatic Pancreatic Cancer That Cannot Be Removed By SurgeryCompletedNCT00303758Phase 3
41Gemcitabine and Capecitabine With or Without Vaccine Therapy in Treating Patients With Locally Advanced or Metastatic Pancreatic CancerCompletedNCT00425360Phase 3
42Gemcitabine With or Without Capecitabine in Treating Patients With Locally Advanced or Metastatic Pancreatic CancerCompletedNCT00032175Phase 3
43NEOadjuvant Gemcitabine/Oxaliplatin Plus Adjuvant Gemcitabine in Resectable PAncreatic CancerCompletedNCT01521702Phase 3
44Standardization of Surgery on the Pancreatic CancerCompletedNCT00679913Phase 3
45Fentanyl Sublingual Spray in Treating Patients With Breakthrough Cancer PainCompletedNCT00538850Phase 3
46Study Of Gemcitabine Plus AG-013736 Versus Gemcitabine For Advanced Pancreatic Cancer.CompletedNCT00471146Phase 3
47Ondansetron With or Without Dexamethasone to Prevent Vomiting in Patients Receiving Radiation Therapy to the Upper AbdomenCompletedNCT00016380Phase 3
48An Analysis of the Response of Human Tumor Microvascular Endothelium to Ionizing RadiationCompletedNCT00132704Phase 3
49Efficacy and Safety of Everolimus (RAD001) Compared to Placebo in Patients With Advanced Neuroendocrine TumorsCompletedNCT00510068Phase 3
50Comprehensive Electronic Cancer Support System for the Treatment of Cancer Related SymptomsCompletedNCT01640522Phase 3

Search NIH Clinical Center for Pancreas Adenocarcinoma

Genetic Tests for Pancreas Adenocarcinoma

About this section

Anatomical Context for Pancreas Adenocarcinoma

About this section

MalaCards organs/tissues related to Pancreas Adenocarcinoma:

33
Pancreas, Liver, Lung, Breast, Kidney, Endothelial, T cells

Animal Models for Pancreas Adenocarcinoma or affiliated genes

About this section

MGI Mouse Phenotypes related to Pancreas Adenocarcinoma:

38 (show all 25)
idDescriptionMGI Source AccessionScoreTop Affiliating Genes
1MP:00011869.9CDKN2A, EGFR, KRAS, NRAS, TP53
2MP:00053719.5BRCA2, EGFR, FOXP3, KRAS, NRAS, SMAD4
3MP:00053679.5EGFR, ERCC1, FOXP3, HRAS, KRAS, SMAD4
4MP:00053889.4AKT1, CDKN2A, EGFR, FOXP3, HRAS, KRAS
5MP:00053829.4EGFR, FOXP3, HRAS, KRAS, NRAS, SMAD4
6MP:00030129.1CDH1, CDKN2A, EGFR, FOXP3, HRAS, KRAS
7MP:00053808.8AKT1, BRCA2, CDH1, CDKN2A, EGFR, ERCC1
8MP:00053708.7AKT1, BHLHA15, CDKN2A, EGFR, ERCC1, FOXP3
9MP:00053868.7AKT1, BRCA2, CDKN2A, ERCC1, FOXP3, HRAS
10MP:00053858.6AKT1, CDH1, CDKN2A, EGFR, FOXP3, HRAS
11MP:00053818.5BHLHA15, BRCA2, CDH1, CDKN2A, EGFR, FOXP3
12MP:00028738.4AKT1, BRCA2, CDH1, EGFR, FOXP3, HRAS
13MP:00053898.3AKT1, BHLHA15, BRCA2, CDH1, CDKN2A, EGFR
14MP:00020068.2AKT1, BHLHA15, BRCA2, CDH1, CDKN2A, EGFR
15MP:00053848.1AKT1, ANXA8L1, BRCA2, CDH1, CDKN2A, EGFR
16MP:00053798.0AKT1, BHLHA15, BRCA2, CDH1, CDKN2A, EGFR
17MP:00107718.0AKT1, BHLHA15, BRCA2, CDH1, CDKN2A, EGFR
18MP:00053977.9AKT1, ANXA8L1, BRCA2, CDKN2A, EGFR, ERCC1
19MP:00053907.9AKT1, BRCA2, CDKN2A, EGFR, ERCC1, HRAS
20MP:00053767.8AKT1, BHLHA15, BRCA2, CDH1, CDKN2A, EGFR
21MP:00053877.8AKT1, ANXA8L1, BRCA2, CDH1, CDKN2A, EGFR
22MP:00053787.6AKT1, BHLHA15, BRCA2, CDH1, CDKN2A, EGFR
23MP:00107687.4AKT1, BHLHA15, BRCA2, CDH1, CDKN2A, EGFR

Publications for Pancreas Adenocarcinoma

About this section

Articles related to Pancreas Adenocarcinoma:

(show all 25)
idTitleAuthorsYear
1
Expression of multidrug resistance-associated proteins and their relation to postoperative individualized chemotherapy in gastric cancer. (25304659)
2014
2
Combined transdiaphragmatic off-pump and minimally invasive coronary artery bypass with right gastroepiploic artery and abdominal aortic aneurysm repair. (23997852)
2013
3
Predictors of the therapeutic response in hepatitis C. A 2013 update. (24268305)
2013
4
Off-pump coronary surgery in a patient with multiple sclerosis. (24364009)
2013
5
Clusterin in Alzheimer's disease: a player in the biological behavior of amyloid-beta. (24353014)
2013
6
Diagnosis and management of primary hyperparathyroidism in Europe. (22566664)
2012
7
Expression of hypoxia-inducible factor (HIF)-1a-vascular endothelial growth factor (VEGF)-inhibitory growth factor (ING)-4- axis in sarcoidosis patients. (23181555)
2012
8
Local IgE production in nonatopic nasal polyposis. (20122344)
2010
9
A role for casein kinase 1 epsilon in the locomotor stimulant response to methamphetamine. (19050854)
2009
10
Involvement of IL-10 and Bcl-2 in resistance against an asbestos-induced apoptosis of T cells. (16850164)
2006
11
Efficacy and safety of the cyclooxygenase 2 inhibitors parecoxib and valdecoxib in patients undergoing coronary artery bypass surgery. (12830070)
2003
12
Patient compliance with phlebotomy therapy for iron overload associated with hemochromatosis. (14499790)
2003
13
Acute myeloid leukemia and myelodysplastic syndrome after doxorubicin-cyclophosphamide adjuvant therapy for operable breast cancer: the National Surgical Adjuvant Breast and Bowel Project Experience. (12663705)
2003
14
Rat liver bile acid CoA:amino acid N-acyltransferase: expression, characterization, and peroxisomal localization. (12951368)
2003
15
Trypanosoma cruzi: molecular cloning and characterization of the S-adenosylhomocysteine hydrolase. (14969692)
2003
16
Comprehensive genome sequence analysis of a breast cancer amplicon. (11381030)
2001
17
Combined use of novel epithelial (MOC-31) and mesothelial (HBME-1) immunohistochemical markers for optimal first line diagnostic distinction between mesothelioma and metastatic carcinoma in pleura. (11422496)
2001
18
Coccidioidomycosis in workers at an archeologic site--Dinosaur National Monument, Utah, June-July 2001. (11724157)
2001
19
Structural and functional differences between 3-repeat and 4-repeat tau isoforms. Implications for normal tau function and the onset of neurodegenetative disease. (10984497)
2000
20
Screening for familial colorectal cancer. (8949666)
1996
21
Evidence of progesterone dependence in ovulation induced by human chorionic gonadotropin in female rabbits. (7920056)
1994
22
Effect of angiotensin-converting-enzyme inhibition on bradykinin metabolism by vascular endothelial cells. (8388656)
1993
23
Spontaneous ascites filtration and reinfusion (SAFR) as ambulatory chronic treatment for hepatorenal syndrome. (3837486)
1985
24
Endocardial fibroelastosis and infantile polycystic disease. (4062721)
1985
25
Lactose intolerance among Mexican Americans. (1146721)
1975

Variations for Pancreas Adenocarcinoma

About this section

Expression for genes affiliated with Pancreas Adenocarcinoma

About this section
Search GEO for disease gene expression data for Pancreas Adenocarcinoma.

Pathways for genes affiliated with Pancreas Adenocarcinoma

About this section

Pathways related to Pancreas Adenocarcinoma according to GeneCards Suite gene sharing:

(show top 50)    (show all 83)
idSuper pathwaysScoreTop Affiliating Genes
19.9HRAS, KRAS, NRAS
29.9HRAS, KRAS, NRAS
39.9HRAS, KRAS, NRAS
49.9HRAS, KRAS, NRAS
5
Show member pathways
9.7HRAS, KRAS, NRAS
69.7AKT1, CDH1, EGFR
79.6EGFR, HRAS, KRAS, NRAS
8
Show member pathways
9.6EGFR, HRAS, KRAS, NRAS
99.6EGFR, HRAS, KRAS, NRAS
109.5AKT1, HRAS, KRAS, NRAS, SMAD4
11
Show member pathways
9.5AKT1, HRAS, KRAS, NRAS, SMAD4
129.5AKT1, HRAS, KRAS, NRAS, SMAD4
139.5CDKN2A, HRAS, KRAS, NRAS, TP53
149.5AKT1, CDH1, EGFR, HRAS
159.5CDH1, HRAS, KRAS, NRAS, TP53
16
Show member pathways
9.5AKT1, HRAS, KRAS, NRAS, TP53
17
Show member pathways
9.5AKT1, HRAS, KRAS, NRAS, TP53
18
Show member pathways
9.5AKT1, HRAS, KRAS, NRAS, TP53
19
Show member pathways
9.5AKT1, HRAS, KRAS, NRAS, TP53
209.5AKT1, HRAS, KRAS, NRAS, TP53
219.5AKT1, HRAS, KRAS, NRAS, TP53
229.4AKT1, CDH1, HRAS, KRAS, NRAS
239.4AKT1, EGFR, HRAS, KRAS, NRAS
24
Show member pathways
9.4AKT1, EGFR, HRAS, KRAS, NRAS
25
Show member pathways
9.4AKT1, EGFR, HRAS, KRAS, NRAS
26
Show member pathways
9.4AKT1, EGFR, HRAS, KRAS, NRAS
27
Show member pathways
9.3AKT1, CDKN2A, HRAS, KRAS, NRAS, TP53
28
Show member pathways
9.2AKT1, EGFR, HRAS, KRAS, NRAS, SMAD4
299.2CDKN2A, EGFR, HRAS, KRAS, NRAS, TP53
309.2AKT1, CDH1, EGFR, MUC1, TP53
319.2AKT1, EGFR, HRAS, KRAS, NRAS, TP53
329.2AKT1, EGFR, HRAS, KRAS, NRAS, TP53
339.2AKT1, EGFR, HRAS, KRAS, NRAS, TP53
34
Show member pathways
9.2AKT1, EGFR, HRAS, KRAS, NRAS, TP53
35
Show member pathways
9.2AKT1, EGFR, HRAS, KRAS, NRAS, TP53
369.2AKT1, EGFR, HRAS, KRAS, NRAS, TP53
379.2AKT1, EGFR, HRAS, KRAS, NRAS, TP53
38
Show member pathways
9.2AKT1, EGFR, HRAS, KRAS, NRAS, TP53
39
Show member pathways
9.2AKT1, EGFR, HRAS, KRAS, NRAS, TP53
409.1AKT1, CDH1, EGFR, KRAS, SMAD4, TP53
419.1AKT1, BRCA2, EGFR, KRAS, SMAD4, TP53
429.1AKT1, CDKN2A, HRAS, KRAS, NRAS, SMAD4
439.0CDH1, CDKN2A, EGFR, HRAS, KRAS, NRAS
449.0AKT1, CDKN2A, EGFR, HRAS, KRAS, NRAS
45
Show member pathways
8.9AKT1, CDH1, EGFR, HRAS, KRAS, MUC1
468.9AKT1, BRCA2, CDH1, EGFR, KRAS, SMAD4
47
Show member pathways
8.8AKT1, CDH1, EGFR, HRAS, KRAS, NRAS
48
Show member pathways
8.5AKT1, BRCA2, CDKN2A, EGFR, HRAS, KRAS
49
Show member pathways
8.4AKT1, BRCA2, CDH1, CDKN2A, EGFR, HRAS
508.3AKT1, BRCA2, CDH1, CDKN2A, EGFR, HRAS

GO Terms for genes affiliated with Pancreas Adenocarcinoma

About this section

Biological processes related to Pancreas Adenocarcinoma according to GeneCards Suite gene sharing:

(show all 18)
idNameGO IDScoreTop Affiliating Genes
1striated muscle cell differentiationGO:005114610.6AKT1, KRAS
2apoptotic mitochondrial changesGO:000863710.6AKT1, CDKN2A
3stimulatory C-type lectin receptor signaling pathwayGO:000222310.4HRAS, KRAS, NRAS
4cellular response to glucose starvationGO:004214910.3BHLHA15, TP53
5replicative senescenceGO:009039910.3CDKN2A, TP53
6cell agingGO:000756910.2BRCA2, HRAS, TP53
7negative regulation of cell growthGO:003030810.2CDKN2A, SMAD4, TP53
8DNA damage response, signal transduction by p53 class mediator resulting in transcription of p21 class mediatorGO:000697810.1BRCA2, MUC1, TP53
9regulation of long-term neuronal synaptic plasticityGO:004816910.1HRAS, KRAS
10leukocyte migrationGO:005090010.0HRAS, KRAS, NRAS
11ERBB2 signaling pathwayGO:00381289.9AKT1, EGFR, HRAS, KRAS, NRAS
12cellular response to DNA damage stimulusGO:00069749.6AKT1, BRCA2, ERCC1, TP53
13positive regulation of transcription, DNA-templatedGO:00458939.6BRCA2, CDH1, CDKN2A, FOXP3, SMAD4, TP53
14apoptotic processGO:00069159.6AKT1, CDH1, CDKN2A, HRAS, TP53
15vascular endothelial growth factor receptor signaling pathwayGO:00480109.6AKT1, EGFR, HRAS, KRAS, NRAS
16insulin receptor signaling pathwayGO:00082869.5AKT1, EGFR, HRAS, KRAS, NRAS
17cell proliferationGO:00082839.1AKT1, BRCA2, EGFR, ERCC1
18positive regulation of transcription from RNA polymerase II promoterGO:00459449.0AKT1, CDKN2A, EGFR, FOXP3, HRAS, TP53

Sources for Pancreas Adenocarcinoma

About this section
2CDC
14ExPASy
15FDA
16FMA
24GTR
25HGMD
26HMDB
27ICD10
28ICD10 via Orphanet
29ICD9CM
30IUPHAR
31KEGG
34MedGen
36MeSH
37MESH via Orphanet
38MGI
41NCI
42NCIt
43NDF-RT
46NINDS
47Novoseek
49OMIM
50OMIM via Orphanet
54PubMed
55QIAGEN
60SNOMED-CT via Orphanet
64Tumor Gene Family of Databases
65UMLS
66UMLS via Orphanet